Urine 5MedC, a marker of DNA methylation, in the progression of chronic kidney disease

Akifumi Onishi, Hitoshi Sugiyama, Masashi Kitagawa, Toshio Yamanari, Keiko Tanaka, Ayu Ogawa-Akiyama, Yuzuki Kano, Koki Mise, Katsuyuki Tanabe, Hiroshi Morinaga, Masaru Kinomura, Haruhito Adam Uchida, Jun Wada

Research output: Contribution to journalArticle

Abstract

Background. Alterations in DNA methylation may be involved in disease progression in patients with chronic kidney disease (CKD). Recent studies have suggested that 5-methyl-2′-deoxycytidine (5MedC) may be a marker of hypermethylation of DNA. Currently, there is no information available regarding the urine levels of 5MedC and its association with the progression of CKD. Method. We examined the urine levels of 5MedC in spot urine samples from 308 patients with CKD (median age: 56 years, male: 53.2%, and glomerulonephritis: 51.0%) using a competitive enzyme-linked immunosorbent assay and investigated the relationships among urine 5MedC, urine albumin, urine α1-microglobulin (α1MG), and the laboratory parameters associated with CKD. The patients were followed for three years to evaluate renal endpoints in a prospective manner. Results. The urine 5MedC level was significantly increased in the later stages of CKD compared to the early to middle stages of CKD. In multiple logistic regression models, urine 5MedC was significantly associated with the prediction of later CKD stages. Urine 5MedC (median value, 65.9 μmol/gCr) was significantly able to predict a 30% decline in the estimated GFR or a development of end-stage renal disease when combined with macroalbuminuria or an increased level of urine α1MG (median value, 5.7 mg/gCr). Conclusion. The present data demonstrate that the urine 5MedC level is associated with a reduced renal function and can serve as a novel and potent biomarker for predicting the renal outcome in CKD patients. Further studies will be necessary to elucidate the role of urine DNA methylation in the progression of CKD.

Original languageEnglish
Article number5432453
JournalDisease markers
Volume2019
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

5-methyldeoxycytidine
DNA Methylation
Chronic Renal Insufficiency
Urine
Kidney
Logistic Models

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Urine 5MedC, a marker of DNA methylation, in the progression of chronic kidney disease. / Onishi, Akifumi; Sugiyama, Hitoshi; Kitagawa, Masashi; Yamanari, Toshio; Tanaka, Keiko; Ogawa-Akiyama, Ayu; Kano, Yuzuki; Mise, Koki; Tanabe, Katsuyuki; Morinaga, Hiroshi; Kinomura, Masaru; Uchida, Haruhito Adam; Wada, Jun.

In: Disease markers, Vol. 2019, 5432453, 01.01.2019.

Research output: Contribution to journalArticle

@article{36e761e7ab0d45dda43a643f0d95d96b,
title = "Urine 5MedC, a marker of DNA methylation, in the progression of chronic kidney disease",
abstract = "Background. Alterations in DNA methylation may be involved in disease progression in patients with chronic kidney disease (CKD). Recent studies have suggested that 5-methyl-2′-deoxycytidine (5MedC) may be a marker of hypermethylation of DNA. Currently, there is no information available regarding the urine levels of 5MedC and its association with the progression of CKD. Method. We examined the urine levels of 5MedC in spot urine samples from 308 patients with CKD (median age: 56 years, male: 53.2{\%}, and glomerulonephritis: 51.0{\%}) using a competitive enzyme-linked immunosorbent assay and investigated the relationships among urine 5MedC, urine albumin, urine α1-microglobulin (α1MG), and the laboratory parameters associated with CKD. The patients were followed for three years to evaluate renal endpoints in a prospective manner. Results. The urine 5MedC level was significantly increased in the later stages of CKD compared to the early to middle stages of CKD. In multiple logistic regression models, urine 5MedC was significantly associated with the prediction of later CKD stages. Urine 5MedC (median value, 65.9 μmol/gCr) was significantly able to predict a 30{\%} decline in the estimated GFR or a development of end-stage renal disease when combined with macroalbuminuria or an increased level of urine α1MG (median value, 5.7 mg/gCr). Conclusion. The present data demonstrate that the urine 5MedC level is associated with a reduced renal function and can serve as a novel and potent biomarker for predicting the renal outcome in CKD patients. Further studies will be necessary to elucidate the role of urine DNA methylation in the progression of CKD.",
author = "Akifumi Onishi and Hitoshi Sugiyama and Masashi Kitagawa and Toshio Yamanari and Keiko Tanaka and Ayu Ogawa-Akiyama and Yuzuki Kano and Koki Mise and Katsuyuki Tanabe and Hiroshi Morinaga and Masaru Kinomura and Uchida, {Haruhito Adam} and Jun Wada",
year = "2019",
month = "1",
day = "1",
doi = "10.1155/2019/5432453",
language = "English",
volume = "2019",
journal = "Disease Markers",
issn = "0278-0240",
publisher = "IOS Press",

}

TY - JOUR

T1 - Urine 5MedC, a marker of DNA methylation, in the progression of chronic kidney disease

AU - Onishi, Akifumi

AU - Sugiyama, Hitoshi

AU - Kitagawa, Masashi

AU - Yamanari, Toshio

AU - Tanaka, Keiko

AU - Ogawa-Akiyama, Ayu

AU - Kano, Yuzuki

AU - Mise, Koki

AU - Tanabe, Katsuyuki

AU - Morinaga, Hiroshi

AU - Kinomura, Masaru

AU - Uchida, Haruhito Adam

AU - Wada, Jun

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background. Alterations in DNA methylation may be involved in disease progression in patients with chronic kidney disease (CKD). Recent studies have suggested that 5-methyl-2′-deoxycytidine (5MedC) may be a marker of hypermethylation of DNA. Currently, there is no information available regarding the urine levels of 5MedC and its association with the progression of CKD. Method. We examined the urine levels of 5MedC in spot urine samples from 308 patients with CKD (median age: 56 years, male: 53.2%, and glomerulonephritis: 51.0%) using a competitive enzyme-linked immunosorbent assay and investigated the relationships among urine 5MedC, urine albumin, urine α1-microglobulin (α1MG), and the laboratory parameters associated with CKD. The patients were followed for three years to evaluate renal endpoints in a prospective manner. Results. The urine 5MedC level was significantly increased in the later stages of CKD compared to the early to middle stages of CKD. In multiple logistic regression models, urine 5MedC was significantly associated with the prediction of later CKD stages. Urine 5MedC (median value, 65.9 μmol/gCr) was significantly able to predict a 30% decline in the estimated GFR or a development of end-stage renal disease when combined with macroalbuminuria or an increased level of urine α1MG (median value, 5.7 mg/gCr). Conclusion. The present data demonstrate that the urine 5MedC level is associated with a reduced renal function and can serve as a novel and potent biomarker for predicting the renal outcome in CKD patients. Further studies will be necessary to elucidate the role of urine DNA methylation in the progression of CKD.

AB - Background. Alterations in DNA methylation may be involved in disease progression in patients with chronic kidney disease (CKD). Recent studies have suggested that 5-methyl-2′-deoxycytidine (5MedC) may be a marker of hypermethylation of DNA. Currently, there is no information available regarding the urine levels of 5MedC and its association with the progression of CKD. Method. We examined the urine levels of 5MedC in spot urine samples from 308 patients with CKD (median age: 56 years, male: 53.2%, and glomerulonephritis: 51.0%) using a competitive enzyme-linked immunosorbent assay and investigated the relationships among urine 5MedC, urine albumin, urine α1-microglobulin (α1MG), and the laboratory parameters associated with CKD. The patients were followed for three years to evaluate renal endpoints in a prospective manner. Results. The urine 5MedC level was significantly increased in the later stages of CKD compared to the early to middle stages of CKD. In multiple logistic regression models, urine 5MedC was significantly associated with the prediction of later CKD stages. Urine 5MedC (median value, 65.9 μmol/gCr) was significantly able to predict a 30% decline in the estimated GFR or a development of end-stage renal disease when combined with macroalbuminuria or an increased level of urine α1MG (median value, 5.7 mg/gCr). Conclusion. The present data demonstrate that the urine 5MedC level is associated with a reduced renal function and can serve as a novel and potent biomarker for predicting the renal outcome in CKD patients. Further studies will be necessary to elucidate the role of urine DNA methylation in the progression of CKD.

UR - http://www.scopus.com/inward/record.url?scp=85069777346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069777346&partnerID=8YFLogxK

U2 - 10.1155/2019/5432453

DO - 10.1155/2019/5432453

M3 - Article

C2 - 31354889

AN - SCOPUS:85069777346

VL - 2019

JO - Disease Markers

JF - Disease Markers

SN - 0278-0240

M1 - 5432453

ER -